RU2010152690A - Белки, связывающие рецептор интерлейкина-21 - Google Patents

Белки, связывающие рецептор интерлейкина-21 Download PDF

Info

Publication number
RU2010152690A
RU2010152690A RU2010152690/10A RU2010152690A RU2010152690A RU 2010152690 A RU2010152690 A RU 2010152690A RU 2010152690/10 A RU2010152690/10 A RU 2010152690/10A RU 2010152690 A RU2010152690 A RU 2010152690A RU 2010152690 A RU2010152690 A RU 2010152690A
Authority
RU
Russia
Prior art keywords
antigen binding
binding fragment
binding protein
protein
antigen
Prior art date
Application number
RU2010152690/10A
Other languages
English (en)
Russian (ru)
Inventor
Лэйрд БЛУМ (US)
Лэйрд БЛУМ
Давиндер ДЖИЛЛ (US)
Давиндер ДЖИЛЛ
Юлия ВУГМЕЙСТЕР (US)
Юлия ВУГМЕЙСТЕР
Дебора А. ЯНГ (US)
Дебора А. Янг
Дэвид ЛОУ (GB)
Дэвид ЛОУ
Вия ВАЛЬГЕ-АРЧЕР (GB)
Вия ВАЛЬГЕ-АРЧЕР
Original Assignee
УАЙТ ЭлЭлСи (US)
УАЙТ ЭлЭлСи
Медиммун Лимитед (Gb)
Медиммун Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41112652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2010152690(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by УАЙТ ЭлЭлСи (US), УАЙТ ЭлЭлСи, Медиммун Лимитед (Gb), Медиммун Лимитед filed Critical УАЙТ ЭлЭлСи (US)
Publication of RU2010152690A publication Critical patent/RU2010152690A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2010152690/10A 2008-05-23 2009-05-26 Белки, связывающие рецептор интерлейкина-21 RU2010152690A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5550008P 2008-05-23 2008-05-23
US61/055,500 2008-05-23

Publications (1)

Publication Number Publication Date
RU2010152690A true RU2010152690A (ru) 2012-06-27

Family

ID=41112652

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010152690/10A RU2010152690A (ru) 2008-05-23 2009-05-26 Белки, связывающие рецептор интерлейкина-21

Country Status (20)

Country Link
US (2) US8163884B2 (https=)
EP (1) EP2297199A1 (https=)
JP (1) JP2011523849A (https=)
KR (1) KR20110040773A (https=)
CN (1) CN102105491A (https=)
AR (1) AR071885A1 (https=)
AU (1) AU2009248809A1 (https=)
CA (1) CA2724915A1 (https=)
CL (1) CL2009001284A1 (https=)
CO (1) CO6382184A2 (https=)
IL (1) IL209328A0 (https=)
MX (1) MX2010012811A (https=)
MY (1) MY149448A (https=)
NZ (1) NZ589330A (https=)
PE (1) PE20100141A1 (https=)
RU (1) RU2010152690A (https=)
SA (1) SA109300315B1 (https=)
TW (1) TW201000129A (https=)
WO (1) WO2009143523A1 (https=)
ZA (1) ZA201008335B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
CA2785678C (en) * 2009-12-25 2018-12-18 Sekisui Medical Co., Ltd. Human insulin assay and assay reagent
ES2628841T3 (es) * 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1
US9309318B2 (en) * 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
US20190185559A1 (en) * 2016-09-02 2019-06-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
EP3687565A1 (en) 2017-09-27 2020-08-05 Alexion Pharmaceuticals, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
EP1881070B1 (en) 1999-03-09 2012-10-03 Zymogenetics, Inc. Human cytokine as ligand of the zalpha receptor and uses thereof
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2000069880A1 (en) 1999-05-18 2000-11-23 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
ES2279809T3 (es) * 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
ES2276795T3 (es) 2000-05-11 2007-07-01 Genetics Institute, Llc Mu-1, miembro de la familia del receptor de citoquina.
DK1451322T3 (da) * 2001-11-05 2010-02-01 Zymogenetics Inc Il-21-antagonister
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
MXPA04012116A (es) * 2002-06-07 2005-04-19 Zymogenetics Inc Uso del il-21 en cancer y otras aplicaciones terapeuticas.
CN1688340A (zh) * 2002-07-15 2005-10-26 韦思公司 调节t辅助(th)细胞发育和功能的方法和组合物
CA2518371A1 (en) * 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
KR20060015482A (ko) * 2003-03-21 2006-02-17 와이어쓰 인터루킨-21/인터루킨-21 수용체의 작용제를 이용한면역장애의 치료
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
US20060024268A1 (en) * 2004-05-19 2006-02-02 Wyeth Modulation of immunoglobulin production and atopic disorders
CN101052419A (zh) * 2004-08-05 2007-10-10 惠氏公司 拮抗白介素－21受体活性
CA2574848A1 (en) * 2004-08-05 2006-12-21 Wyeth Antagonizing interleukin-21 receptor activity
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2008081198A1 (en) 2007-01-05 2008-07-10 Imperial Innovations Ltd Blood assays for predicting inflammatory responses

Also Published As

Publication number Publication date
MX2010012811A (es) 2011-05-19
KR20110040773A (ko) 2011-04-20
US20090298167A1 (en) 2009-12-03
PE20100141A1 (es) 2010-02-22
WO2009143523A1 (en) 2009-11-26
NZ589330A (en) 2012-12-21
CN102105491A (zh) 2011-06-22
US20120264919A1 (en) 2012-10-18
SA109300315B1 (ar) 2012-08-28
IL209328A0 (en) 2011-01-31
ZA201008335B (en) 2014-04-30
CL2009001284A1 (es) 2009-11-27
JP2011523849A (ja) 2011-08-25
CA2724915A1 (en) 2009-11-26
AR071885A1 (es) 2010-07-21
MY149448A (en) 2013-08-30
AU2009248809A1 (en) 2009-11-26
TW201000129A (en) 2010-01-01
US8163884B2 (en) 2012-04-24
CO6382184A2 (es) 2012-02-15
EP2297199A1 (en) 2011-03-23

Similar Documents

Publication Publication Date Title
RU2467016C2 (ru) Антитела к il-22 человека и их применение
RU2010152690A (ru) Белки, связывающие рецептор интерлейкина-21
WO2021244089A1 (zh) 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用
CN116063464B (zh) 冠状病毒的抗体或其抗原结合片段
JP2009531023A5 (https=)
JP2010535012A5 (https=)
JP2011510654A5 (https=)
RU2009138922A (ru) Новые анти-r7v-антитела и их применения
RU2010136940A (ru) Антитела против альфа5-бета1 и их применение
TW200745164A (en) Gene recombination antibodies composition
RU2010123693A (ru) МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С hGM-CSF, И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ МЕДИЦИНСКОГО НАЗНАЧЕНИЯ
SI2573121T1 (en) Antibodies that bind IL-4 and/or IL-13 and their uses
CA2797981A1 (en) Heterodimeric proteins and methods for producing and purifying them
RU2012149858A (ru) Получение гетеромультимерных белков
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
RU2011138154A (ru) Белки специфического связывания и их применения
JPWO2022040482A5 (https=)
JP2014509187A5 (https=)
RU2008106893A (ru) Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
RU2010129558A (ru) ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С АЛЬФА-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173
JP2007526233A5 (https=)
PE20060376A1 (es) ANTICUERPO MONOCLONAL HUMANIZADO O QUIMERICO COMO INHIBIDOR DE hIL-3
WO2022061594A1 (zh) 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用
RU2013133846A (ru) Антитела против il-18 и их применение
JP2014530001A5 (https=)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20140505